Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endoxifen supplementation guided by CYP2D6 genotype/phenotype in tamoxifen-treated breast cancer
2016-000418-31Phase 2Completed
- Sponsor
- Bosch
- Start
- Dec 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of z-endoxifen and tamoxifen in breast cancer and ductal carcinoma in situ (DCIS) (3 arms), sponsored by Bosch. Primary endpoint: Proportion achieving target steady-state (Z)-endoxifen concentration. Started Dec 2018; status: completed.
02
Drugs
z-endoxifentamoxifen
03
Conditions
breast cancerductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on 2016-000418-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000418-31.